Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) saw an uptick in trading volume on Monday. 7,874,852 shares traded hands during trading, an increase of 503% from the average daily volume of 1,306,700 shares. The stock last traded at $7.3410 and had previously closed at $8.87.
Analyst Ratings Changes
Several research analysts have commented on the stock. Barclays initiated coverage on shares of Cybin in a report on Friday, September 18th. They issued an "overweight" rating and a $35.00 price target for the company. TD Cowen upped their price target on shares of Cybin from $8.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Wells Fargo & Company upped their price target on shares of Cybin from $16.00 to $22.00 and gave the stock an "overweight" rating in a report on Thursday, October 22nd. Finally, Wall Street Zen downgraded Cybin from a "sell" rating to a "strong sell" rating in a research report on Saturday, November 7th. Six analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $47.33.
View Our Latest Report on Cybin
Cybin Price Performance
The firm has a market capitalization of $628.82 million, a PE ratio of -2.61 and a beta of 0.64. The business's 50 day moving average is $11.24 and its two-hundred day moving average is $7.81.
Cybin (NASDAQ:HELP - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.74). Analysts expect that Cybin Inc. will post -2.95 EPS for the current fiscal year.
Insider Activity at Cybin
In other news, CEO Michael Halstead purchased 100,000 shares of the stock in a transaction on Monday, September 21st. The shares were acquired at an average price of $13.47 per share, for a total transaction of $1,347,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,568 shares of the company's stock, valued at approximately $2,270,610.96. This trade represents a 145.84% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CFO Greg Cavers purchased 3,000 shares of the stock in a transaction on Tuesday, September 29th. The shares were purchased at an average price of $12.91 per share, for a total transaction of $38,730.00. Following the transaction, the chief financial officer directly owned 3,000 shares of the company's stock, valued at approximately $38,730. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 688,000 shares of company stock valued at $8,422,830 over the last ninety days. 15.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Cybin
A number of large investors have recently modified their holdings of the company. AXQ Capital LP bought a new stake in Cybin in the 2nd quarter worth approximately $75,000. Farther Finance Advisors LLC grew its position in Cybin by 927.4% during the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company's stock valued at $280,000 after acquiring an additional 20,597 shares during the last quarter. State Street Corp bought a new position in Cybin during the third quarter valued at approximately $363,000. Pale Fire Capital SE purchased a new position in shares of Cybin during the second quarter worth approximately $1,015,000. Finally, WealthPlan Investment Management LLC purchased a new position in shares of Cybin during the third quarter worth approximately $1,272,000. 17.94% of the stock is owned by hedge funds and other institutional investors.
About Cybin
(
Get Free Report)
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company's pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.